Targeting proteases involved in the viral replication of SARS-CoV-2 by sesquiterpene lactones from chicory (Cichorium intybus L.).

SARS-CoV-2 is a highly transmissible and pathogenic coronavirus causing a respiratory disease that emerged in 2019, leading to a public health emergency situation which continues to date. The treatment options are still very limited and vaccines available are less effective against new variants. SARS-CoV-2 enzymes, namely main protease (Mpro) and papain-like protease (PLpro), play a pivotal role in the viral life cycle, making them a putative drug target. Here, we described for the first time the potential inhibitory activity of chicory extract against both proteases. Besides, we have identified that the four most abundant sesquiterpene lactones in chicory inhibited these proteases, showing an effective binding in the active sites of Mpro and PLpro. This paper provides new insight for further drug development or food-based strategies for the prevention of SARS-CoV-2 by targeting viral proteases.

[1]  Hao Tan,et al.  Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease , 2022, Journal of medicinal chemistry.

[2]  M. Kumar,et al.  Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies , 2022, Frontiers in Microbiology.

[3]  D. Komander,et al.  Inhibitors of SARS-CoV-2 PLpro , 2022, Frontiers in Chemistry.

[4]  U. Rova,et al.  Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds , 2022, Computational and Structural Biotechnology Journal.

[5]  K. Murakami,et al.  Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay , 2022, Communications Biology.

[6]  Haihai Jiang,et al.  Potential Inhibitors Targeting Papain-Like Protease of SARS-CoV-2: Two Birds With One Stone , 2022, Frontiers in Chemistry.

[7]  A. Babaei,et al.  Artemisinins in Combating Viral Infections Like SARS-CoV-2, Inflammation and Cancers and Options to Meet Increased Global Demand , 2022, Frontiers in Plant Science.

[8]  T. Brás,et al.  Anti-Inflammatory and Immunoregulatory Action of Sesquiterpene Lactones , 2022, Molecules.

[9]  M. Pinheiro,et al.  SARS-CoV-2 introductions and early dynamics of the epidemic in Portugal , 2022, Communications Medicine.

[10]  A. Jamal,et al.  Antiviral Effects of Artemisinin and Its Derivatives against SARS-CoV-2 Main Protease: Computational Evidences and Interactions with ACE2 Allelic Variants , 2022, Pharmaceuticals.

[11]  Ri-lei Yu,et al.  Design of SARS-CoV-2 Mpro, PLpro dual-target inhibitors based on deep reinforcement learning and virtual screening , 2021, Future medicinal chemistry.

[12]  A. Capriotti,et al.  Characterization of the Trans-Epithelial Transport of Green Tea (C. sinensis) Catechin Extracts with In Vitro Inhibitory Effect against the SARS-CoV-2 Papain-like Protease Activity , 2021, Molecules.

[13]  Malina A. Bakowski,et al.  Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 , 2021, Nature Communications.

[14]  S. Durdağı,et al.  Instant determination of the artemisinin from various Artemisia annua L. extracts by LC‐ESI‐MS/MS and their in‐silico modelling and in vitro antiviral activity studies against SARS‐CoV‐2 , 2021, Phytochemical analysis : PCA.

[15]  K. Oksman-Caldentey,et al.  Chicory Extracts and Sesquiterpene Lactones Show Potent Activity against Bacterial and Fungal Pathogens , 2021, Pharmaceuticals.

[16]  K. Gajiwala,et al.  An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 , 2021, Science.

[17]  R. Preissner,et al.  Reynoutria Rhizomes as a Natural Source of SARS-CoV-2 Mpro Inhibitors–Molecular Docking and In Vitro Study , 2021, Pharmaceuticals.

[18]  F. Abas,et al.  Bioactivities of Phenolic Compounds from Kiwifruit and Persimmon , 2021, Molecules.

[19]  C. Santos,et al.  Sesquiterpene Lactones: Promising Natural Compounds to Fight Inflammation , 2021, Pharmaceutics.

[20]  M. Plazas,et al.  Potential In Vitro Inhibition of Selected Plant Extracts against SARS-CoV-2 Chymotripsin-Like Protease (3CLPro) Activity , 2021, Foods.

[21]  D. Bosch,et al.  Supercritical CO2 Extraction as a Tool to Isolate Anti-Inflammatory Sesquiterpene Lactones from Cichorium intybus L. Roots , 2021, Molecules.

[22]  F. Apone,et al.  Pomegranate Peel Extract as an Inhibitor of SARS-CoV-2 Spike Binding to Human ACE2 Receptor (in vitro): A Promising Source of Novel Antiviral Drugs , 2021, Frontiers in Chemistry.

[23]  Arpit Shukla,et al.  Identifying structural–functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation , 2021, Molecular diversity.

[24]  T. Jin,et al.  Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease , 2021, Frontiers in Chemistry.

[25]  L. Palese,et al.  SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome , 2021, Molecules.

[26]  Lijun Rong,et al.  Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases , 2021, Cell & Bioscience.

[27]  N. Ghosh,et al.  Inhibitory efficacy of RNA virus drugs against SARS-CoV-2 proteins: An extensive study , 2021, Journal of Molecular Structure.

[28]  A. Morice,et al.  Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? , 2021, Lung.

[29]  Leiliang Zhang,et al.  Molecular docking of potential SARS-CoV-2 papain-like protease inhibitors , 2020, Biochemical and Biophysical Research Communications.

[30]  S. Kumari,et al.  Structural insights into SARS-CoV-2 proteins , 2020, Journal of Molecular Biology.

[31]  Qin Xu,et al.  Safety and efficacy of artemisinin-piperaquine for treatment of COVID-19: an open-label, non-randomised and controlled trial , 2020, International Journal of Antimicrobial Agents.

[32]  B. Luan,et al.  Targeting Proteases for Treating COVID-19 , 2020, Journal of proteome research.

[33]  Nayim Sepay,et al.  Anti-COVID-19 terpenoid from marine sources: A docking, admet and molecular dynamics study , 2020, Journal of Molecular Structure.

[34]  Cooper A. Taylor,et al.  Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors , 2020, Nature Communications.

[35]  Chia-en A. Chang,et al.  Insights Into Dynamics of Inhibitor and Ubiquitin-Like Protein Binding in SARS-CoV-2 Papain-Like Protease , 2020, Frontiers in Molecular Biosciences.

[36]  Zhìhóng Hú,et al.  Anti-SARS-CoV-2 Potential of Artemisinins In Vitro , 2020, ACS infectious diseases.

[37]  G. Hummer,et al.  Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity , 2020, Nature.

[38]  D. Moreno,et al.  Chicory (Cichorium intybus L.) as a food ingredient - Nutritional composition, bioactivity, safety, and health claims: A review. , 2020, Food chemistry.

[39]  Chunlong Ma,et al.  Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease , 2020, Cell Research.

[40]  A. Joachimiak,et al.  Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography , 2020, Nature Communications.

[41]  D. Lorne Tyrrell,et al.  Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication , 2020, Nature Communications.

[42]  R. Hilgenfeld,et al.  Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors , 2020, Science.

[43]  Cynthia Liu,et al.  Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases , 2020, ACS central science.

[44]  W. Ko,et al.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges , 2020, International Journal of Antimicrobial Agents.

[45]  Yu Wai Chen,et al.  Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like Protease (3CLpro) Structure: Virtual Screening Reveals Velpatasvir, Ledipasvir, and Other Drug Repurposing Candidates , 2020 .

[46]  W. Liu,et al.  Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV , 2020, Chembiochem : a European journal of chemical biology.

[47]  Zi-feng Yang,et al.  Inhibition of influenza virus via a sesquiterpene fraction isolated from Laggera pterodonta by targeting the NF-κB and p38 pathways , 2017, BMC Complementary and Alternative Medicine.

[48]  Haiyang Liu,et al.  Lindenane sesquiterpenoid dimers from Chloranthus japonicus inhibit HIV-1 and HCV replication. , 2016, Fitoterapia.

[49]  Lijia Yang,et al.  Sesquiterpenes from the fruits of Illicium jiadifengpi and their anti-hepatitis B virus activities. , 2015, Fitoterapia.

[50]  A. Mesecar,et al.  The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds , 2014, Antiviral Research.

[51]  C. Lopes,et al.  Sesquiterpene lactones: Adverse health effects and toxicity mechanisms , 2013, Critical reviews in toxicology.

[52]  C. Wagstaff,et al.  Sesquiterpenoids Lactones: Benefits to Plants and People , 2013, International journal of molecular sciences.

[53]  K. Park,et al.  Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases , 2012, Bioorganic & Medicinal Chemistry.

[54]  F. Tsai,et al.  Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds , 2005, Antiviral Research.

[55]  Po-Huang Liang,et al.  Inhibition of SARS-CoV 3C-like Protease Activity by Theaflavin-3,3′-digallate (TF3) , 2005, Evidence-based complementary and alternative medicine : eCAM.

[56]  C. Lipinski.  Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[57]  Eric D. Brown,et al.  High-Throughput Screening Identifies Inhibitors of the SARS Coronavirus Main Proteinase , 2004, Chemistry & Biology.

[58]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.